NutraLec - Product Description http://www.lectinlabs.com/nutralec_description.

html

NutraLec® - A Nutraceutical for Stomach Ailments

PRODUCT DESCRIPTION

THE PRODUCT

NutraLec is a powder extract from a plant cereal grain commonly found in the human diet. Two
tablespoons in a drink in the morning and two before bedtime is the recommended oral dose.
NutraLec will be marketed under the Dietary Supplement and Health Education Act of 1994
(DSHEA) and product launch is underway.

APPLICATION/THERAPEUTIC AREAS

Treatment of gastritis and ulcers associated with infection caused by H. pylori

Maintenance therapy is believed to prevent recurrence of disease

MECHANISM OF ACTION

NutraLec contains a bioactive carbohydrate-binding protein called lectin that targets H. pylori.
The lectin contained in the product binds specifically to signature carbohydrate sequences on
the bacterium’s cell surface, which abates or destroys the infectivity of H. pylori.

CLINICAL TRIALS IN HUMANS

A pilot, open-labeled clinical trial investigation with NutraLec for the treatment of H. pylori-
infected patients has yielded safe and effective control of infection
Safety: no expected nor reported systemic side effects
A randomized, double-blinded, placebo-controlled clinical trial is currently in progress

WHY NUTRALEC?

Background
H. pylori infection of the stomach can result in a broad spectrum of debilitating disease
outcomes, including gastritis, non-ulcer dyspepsia, peptic ulcer disease, and gastric cancers. In
the U.S. about 50% of the population may be infected with this organism, and currently about 25
million Americans suffer from peptic ulcer disease. Each year there are 500,000 to 850,000 new
cases and more than one million ulcer-related hospitalizations. On a global scale, the frequency
of H. pylori infection is much higher and varies greatly in prevalence in developing countries.

The Problem.
Treatment of H. pylori infection with antimicrobial therapy heals peptic ulcers, eliminates chronic
gastritis and dyspepsia, and may lead to regression of gastric cancer. However, there is currently
no therapy that is 100% effective. Though numerous antibiotics have activity against H. pylori in
vitro, therapy with a single antibiotic is generally ineffective in clinical practice. Successful
treatment often requires combination therapy consisting of 3-4 drugs given for periods of two
weeks or more. Treatment failure occurs frequently and second-line treatments with new
antibiotic regimens are common. Perhaps the single most important factor influencing treatment
failure is the emergence of antibiotic-resistant strains of H. pylori. Therefore, antibiotic therapy
may be quite limited or inadequate in the future. NutraLec is believed to be a safe alternative to

1 of 2 05-04-2011 19:26
NutraLec - Product Description http://www.lectinlabs.com/nutralec_description.html

antibiotics and has been shown to be effective in arresting infection caused by H. pylori.

[CLOSE WINDOW ]

2 of 2 05-04-2011 19:26